Comparison of early cardiovascular risk among Brazilian and African university students

Sousa, Ederson Laurindo Holanda de; Cavalcante, Jânio Emanuel Andrade; Sousa, Daniel Freire de; Ferreira, Jamile Magalhães; Meneses, Richard Rarison Cavalcante; Sousa, Duaran Lopes; Silva, Allyson Jordan Xavier da; Filho, Raimundo Rigoberto Barbosa Xavier; Santos, Elias da Silva; Havt, Alexandre; Damasceno, Nágila Raquel Teixeira; Sampaio, Tiago Lima; Queiroz, Maria Goretti Rodrigues de

doi:10.1016/j.clinbiochem.2019.09.007

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HDL is a lipoprotein that helps remove excess cholesterol from the bloodstream through reverse cholesterol transport. It also has antioxidant action due to its constitutive enzymes, such as paraoxonase, which prevent lipid oxidation and, consequently, atherosclerotic damage (de Sousa et al, 2020).…”

Section: Tyramine Exerts Hypolipidemic and Anti-obesity Effects In Vivomentioning

confidence: 99%

Tyramine exerts hypolipidemic and anti-obesity effects in vivo

Morais

Melo

Dantas

et al. 2022

Braz. J. Pharm. Sci.

Self Cite

View full text Add to dashboard Cite

Obesity and dyslipidemia are conditions often associated with cardiovascular risk, inflammation, oxidative stress, and death. Thus, a new approach has been highlighted to promote research and development of pharmacological tools derived from natural sources. Among the most widely studied groups of substances, polyphenols such as tyramine stand out. This study investigated hypolipidemic and anti-obesity properties of tyramine. Oral toxicity evaluation, models of dyslipidemia and obesity were used. To induce dyslipidemia, Poloxamer-407 (P-407) was administered intraperitoneally. In the hypercholesterolemic and obesity model, specific diet and oral tyramine were provided. After 24h of P-407 administration, tyramine 2 mg/kg (T2) decreased triglycerides (TG) (2057.0 ± 158.5 mg/dL vs. 2838 ± 168.3 mg/dL). After 48h, TG were decreased by T2 (453.0 ± 35.47 vs. 760.2 ± 41.86 mg/dL) and 4 mg/kg (T4) (605.8 ± 26.61 760.2 ± 41.86 mg/dL). T2 reduced total cholesterol (TC) after 24h (309.0 ± 11.17 mg/dL vs. 399.7 ± 15.7 mg/dL); After 48h, 1 mg/kg (T1) (220.5 ± 12.78 mg/dL), T2 (205.8 ± 7.1 mg/dL) and T4 (216.8 ± 12.79 mg/dL), compared to P-407 (275.5 ± 12.1 mg/dL). The treatment decreased thiobarbituric acid reactive substances and nitrite in liver, increased superoxide dismutase, reduced the dietinduced dyslipidemia, decreasing TC around 15%. Tyramine reduced body mass, glucose, and TC after hypercaloric feed. Treatment with 5 mg/L (0.46 ± 0.04 ng/dL) and 10 mg/L (0.44 ± 0.02 ng/dL) reduced plasma insulin (1.18 ± 0.23 ng/dL). Tyramine increased adiponectin at 5 mg/L (1.02 ± 0.02 vs. 0.83 ± 0.02 ng/mL) and 10mg/L (0.96 ± 0.04 ng/mL). In conclusion, tyramine has low toxicity in rodents, has antioxidant effect, reduces plasma triglycerides and cholesterol levels. However, further studies should be conducted in rodents and non-rodents to better understand the pharmacodynamic and pharmacokinetic properties of tyramine.

show abstract

Section: Tyramine Exerts Hypolipidemic and Anti-obesity Effects In Vivomentioning

confidence: 99%